KRAS and non-small cell lung carcinoma: Preclinical studies with KRAS G12C-mutated NSCLC cells exposed to allele-specific inhibitors showed a temporary state of quiescence followed by cell death in some cells, while another group rapidly bypassed the inhibition through upstream stimulation, involving EGFR and AURKA activation, leading to de novo KRAS G12C production [115].